The FDA opened applications for its Commissioner’s National Priority Voucher pilot program offering expedited review timelines of 1-2 months for medicines addressing key U.S. priorities. Eligibility has expanded to include “increasing affordability” alongside onshoring drug development and manufacturing, rare disease treatments, public health crises like universal flu vaccines, and chronic disease interventions. This initiative aims to promote domestic supply chain resilience, pricing innovation, and clinical trial robustness for U.S. patients, facilitating faster access to impactful therapeutics.